Patient preferences for the attributes of a noninvasive treatment for superficial basal cell carcinoma
| Autor: | Klara Mosterd, Nicole W.J. Kelleners-Smeets, Aimee H.M.M. Arits, Brigitte A. B. Essers, Marike R C Hendriks |
|---|---|
| Přispěvatelé: | RS: CAPHRI - R2 - Creating Value-Based Health Care, MUMC+: KIO Kemta (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Dermatologie (9), MEMIC, Dermatologie |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Imiquimod Discrete choice experiment Dermatology SINGLE-BLIND law.invention Superficial basal cell carcinoma 030207 dermatology & venereal diseases 03 medical and health sciences PHOTODYNAMIC THERAPY 0302 clinical medicine Pharmacotherapy Randomized controlled trial law Carcinoma medicine business.industry RANDOMIZED CONTROLLED-TRIAL medicine.disease Patient preference FLUOROURACIL Surgery Clinical trial 030104 developmental biology IMIQUIMOD Radiology business medicine.drug |
| Zdroj: | British Journal of Dermatology, 178(1), E26-E27. Wiley |
| ISSN: | 0007-0963 |
| DOI: | 10.1111/bjd.15782 |
| Popis: | To examine which attributes of a non-invasive treatment for superficial BCC (sBCC) are valued by patients, a discrete choice experiment (DCE) was performed alongside a clinical trial in which methylaminolevulinate photodynamic therapy (MAL-PDT), 5-fluorouracil and imiquimod were compared.1 Treatment options were described by the following attributes: effectiveness, cosmetic result, treatment process and side-effects. Effectiveness was defined as the probability that complete tumour clearance is achieved 12 months after treatment with levels of 75%,80%,85% and 90%.2-4 This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text